Molecular Targeting Technologies, Inc.
A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis.
$3.2MNational Cancer Institute R01 grant
ParticipantActivity from announced rounds
A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis.